Orpea: confirms its target of sales

© Reuters. Orpea: confirms its target of sales

The turnover 2017 was up +10.5% to 3 138,2 ME.

It has been argued by a solid organic growth of +5.4% and that by the dynamics of acquisitions internationally, in particular Spitex in Switzerland, Dr. Dr. Wagner in Austria, Anavita in the Czech Republic and Sanyres in Spain ‘ indicates the group.

The EBITDA thus increased from +15.4% to 547,7 ME, or a margin of 17.5% of sales, up 80 basis points compared to 2016.

The Current Operating Profit is to 394,4 ME (+13,3%), after depreciation and provisions of 153,3 ME (+21,2%) reflecting the increase in real estate property.

The net result (excluding the convertible bond and discounted deferred taxes) amounted to 197,8 ME, in increase of +11.4%, a higher rate than the increase in sales.

‘Orpea confirms its sales target of 3 400 ME for 2018 (+8.3% compared to 2017), which will be accompanied by an EBITDA margin equal to or greater than that achieved in 2017’ announces the direction.

Copyright (c) 2018 CercleFinance.com. All rights reserved.

Like this post? Please share to your friends:
Leave a Reply